Emcure Pharmaceuticals Ltd. announced its consolidated financial results for the second quarter and half-year ended September 30, 2026. The company reported a 24.3% year-on-year increase in revenue to INR 28,205 million. Profit After Tax (PAT) grew by 29.3% to INR 3,251 million, with EBITDA increasing by 30.9% to INR 5,748 million. The results reflect broad-based growth across domestic and international segments.
Emcure Pharmaceuticals Announces Strong Q2 FY27 Results
Emcure Pharmaceuticals Ltd. has announced its consolidated financial results for the second quarter and half-year ended September 30, 2026. The company has demonstrated robust financial performance, with significant year-on-year growth across key metrics.
Key Financial Highlights
Second Quarter FY27 Performance:
- Revenue from operations stood at INR 28,205 Mn, marking a 24.3% increase compared to the same period last year.
- EBITDA grew by 30.9% to INR 5,748 Mn, with an EBITDA margin of 20.4%, an improvement of 103 basis points YoY.
- Profit After Tax (PAT) increased by 29.3% to INR 3,251 Mn, resulting in a PAT margin of 11.5%, up 45 bps YoY.
Half Year FY27 Performance:
- Revenue from operations for the half-year reached INR 54,009 Mn, a 23.6% increase YoY.
- EBITDA for the half-year was INR 10,828 Mn, up 28.6% YoY.
- PAT for the half-year stood at INR 6,176 Mn, a 32.5% increase YoY.
Segmental Performance
The company witnessed broad-based growth across its business segments:
Domestic Business:
- Domestic sales grew by 12.0% to INR 11,553 Mn in Q2 FY27, accounting for 41.0% of consolidated revenue. Growth was primarily driven by the Women’s Health franchise, Cardio-Metabolics, and CNS range.
International Business:
- International sales increased by 34.5% to INR 16,652 Mn, comprising 59.0% of consolidated revenue. Growth was broad-based across Europe, Canada, and the Rest of the World, supported by new launches and continued expansion of existing business.
Management Commentary
Mr. Satish Mehta, Chairman, Managing Director, and CEO, commented, “Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings. Revenue grew 24% year-on-year to INR 28,205 Mn, with India growing 12% and International 34.5%. EBITDA grew 31% to INR 5,748 Mn, with margin at 20.4%, an expansion of about 100 basis points, driven by productivity gains and operating leverage. PAT grew 29% to INR 3,251 Mn. We expect business momentum to sustain into H2FY27.”
Other Developments
The company also provided updates on its R&D pipeline, including product approvals and regulatory filings. Furthermore, the Board approved a composite scheme of amalgamation of its wholly-owned subsidiaries, Zuventus Healthcare Limited and Emcutix Pharmaceuticals Limited, with Emcure Pharmaceuticals Limited, aimed at simplifying the group structure.
Source: BSE
